http://www.ama-assn.org/amednews/2007/05/07/bisb0507.htm
Expensive - by UK standards - if they don't take the adverts. I suspect that the licencing model is such that when the company folds, the software goes away, or alternative and likely more expensive ways of supporting what by then will be a practice asset will be imposable upon users. Whereas with an open source model, none of this applies. Who is an AMA member who could write to the journal? -- Midgley
